Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...

The overall five-year survival rate for people with active multiple myeloma in the United States has increased steadily over time, to more than 62% today. It’s important to remember that even the most ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...

Study reveals multiple high-risk genetic changes predict worse multiple myeloma outcomes across all treatments.

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

Despite these challenges, advances in the field are improving the outlook for people diagnosed with multiple myeloma. As evidence, the five-year overall survival rate in the United States has ...

The company previously teased the overall survival (OS ... of relapsed or refractory multiple myeloma." The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm ...

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...

Thalidomide was the first immunomodulatory agent approved for use in myeloma. Although highly ... Overall response rate; OS: Overall survival; PFS: Progression-free survival; PR: Partial response ...

Panelists discuss how CARTITUDE-4 demonstrated superior progression-free survival and overall response rates with ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.